Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 28 publications
Venetoclax-Augmented RIC Allogeneic HCT With PTCy-Based GVHD Prophylaxis and Venetoclax/Azacitidine Maintenance for Poor Risk MDS and AML.
Journal: Transplantation and cellular therapy
Published: April 28, 2026
Innovations in conditioning and post-transplant maintenance in AML: genomically informed revelations on the graft-versus-leukemia effect.
Journal: Frontiers in immunology
Published: December 20, 2023
Prophylactic maintenance with venetoclax/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AML.
Journal: Blood advances
Published: November 06, 2023
Correction: Integrative analysis identifies an older female-linked AML patient group with better risk in ECOG-ACRIN Cancer Research Group's clinical trial E3999.
Journal: Blood cancer journal
Published: July 05, 2023
Development of a student-created internal medicine frameworks website for healthcare trainees.
Journal: Diagnosis (Berlin, Germany)
Published: February 17, 2023
Last Updated: 09/26/2026